Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review

HIGHLIGHTS

• who: Sławomir Liberski et al. from the Department of Ophthalmology, Poznan University of Medical Sciences, ulAugustyna Szamarzewskiego, Poznan, Poland have published the research: Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review, in the Journal: (JOURNAL) of 20/08/2022
• what: The authors summarize the current state of knowledge concerning using both aflibercept and faricimab in treating DME and nAMD, taking into account the published results of the phase III clinical trials in which these drugs were directly compared. The CST in the fourth week . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.